The dismissive comments about clinical trials are simply untrue. The Brilacidin-OM trial has been slow to progress because of the stringent rules for participation which screen out many potential enrollees. That is why the company is expanding the number of sites for the test.

To claim otherwise with dismissive language is simply wrong. It also is indicative of the true position of those who post in that way -- which is simply to raise doubts among those who are not as familiar with the stock as most of us here are.

Anyone holding this stock is not likely to be scared off by FUD.